Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556682 | 0.89 | EPHX2 (0.52) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL13575194 | 0.89 | EPHX2 (0.52) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL13575195 | 0.89 | EPHX2 (0.52) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL973910 | 0.88 | EPHX2 (0.51) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL974457 | 0.88 | EPHX2 (0.51) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL10297219 | 0.88 | EPHX2 (0.51) | FAAHCNR2EPHX2CNR1FKBP1A | |
| Hydrochloric Acid SCHEMBL973909 | 0.87 | EPHX2 (0.50) | FAAHCNR2EPHX2CNR1FKBP1A | |
| Hydrochloric Acid SCHEMBL973908 | 0.87 | EPHX2 (0.50) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL10297217 | 0.86 | EPHX2 (0.49) | FAAHCNR2EPHX2CNR1FKBP1A | |
| SCHEMBL10131882 | 0.86 | EPHX2 (0.49) | FAAHCNR2EPHX2CNR1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | FAAH 2661/4885CNR2 3873/4885EPHX2 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.